Primary hyperparathyroidism.
Walker MD, Silverberg SJ.
Nat Rev Endocrinol. 2018 Feb;14(2):115-125. doi: 10.1038/nrendo.2017.104. Epub 2017 Sep 8.
Normocalcemic primary hyperparathyroidism.
Cusano NE, Cetani F.
Arch Endocrinol Metab. 2022 Nov 11;66(5):666-677. doi: 10.20945/2359-3997000000556.
Current opinions on nephrolithiasis associated with primary hyperparathyroidism.
Cong X, Shen L, Gu X.
Urolithiasis. 2018 Oct;46(5):453-457. doi: 10.1007/s00240-018-1038-x. Epub 2018 Jan 19.
Primary hyperparathyroidism.
Oberger Marques JV, Moreira CA.
Best Pract Res Clin Rheumatol. 2020 Jun;34(3):101514. doi: 10.1016/j.berh.2020.101514. Epub 2020 Apr 23.
Approach to the Patient: Normocalcemic Primary Hyperparathyroidism.
Liu Y, Sinha Gregory N, Andreopoulou P, Kashyap S, Cusano N.
J Clin Endocrinol Metab. 2025 Feb 18;110(3):e868-e877. doi: 10.1210/clinem/dgae659.
Evaluation for Primary Hyperparathyroidism in Patients Who Present With Nephrolithiasis.
Behrens M, Boyle S, Fingeret AL.
J Surg Res. 2021 Jan;257:79-84. doi: 10.1016/j.jss.2020.07.049. Epub 2020 Aug 17.
Primary hyperparathyroidism and nephrolithiasis.
Vestergaard P.
Ann Endocrinol (Paris). 2015 May;76(2):116-9. doi: 10.1016/j.ando.2015.03.002. Epub 2015 Apr 21.
Sporadic Primary Hyperparathyroidism.
Kim SJ, Shoback DM.
Endocrinol Metab Clin North Am. 2021 Dec;50(4):609-628. doi: 10.1016/j.ecl.2021.07.006.
Parathyroidectomy for nephrolithiasis in primary hyperparathyroidism: Beneficial but not a panacea.
Huang SY, Burchette R, Chung J, Haigh PI.
Surgery. 2022 Jan;171(1):29-34. doi: 10.1016/j.surg.2021.03.077. Epub 2021 Aug 4.
Cardiovascular Risk in Patients with Primary Hyperparathyroidism.
Tournis S, Makris K, Cavalier E, Trovas G.
Curr Pharm Des. 2020;26(43):5628-5636. doi: 10.2174/1381612824999201105165642.
